I-SPY 2: Addition of Pembrolizumab to Neoadjuvant Chemotherapy in HER2-Negative Early Breast Cancer

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
The addition of pembrolizumab to neoadjuvant T → AC “graduated” I-SPY 2 for efficacy, approximately tripling the estimated pCR in TNBC and in HR+/HER2- EBC.
Format: Microsoft PowerPoint (.ppt)
File Size: 629 KB
Released: June 9, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings